Jazz Pharmaceuticals plc (JAZZ)

107,43 -0,89 (-0,82%) Alla chiusura: 04:00PM EDT

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin D04 E5W7
Ireland
353 1 634 7800
https://www.jazzpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 2.800

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Bruce C. Cozadd	Co-Founder, Chairman & CEO	2,45M	13,66M	1964
Ms. Reneé D. Galá	President & COO	1,13M	N/D	1972
Dr. Robert Iannone M.D.	Executive VP and Global Head of Research & Development	1,08M	N/D	1967
Mr. Philip L. Johnson	Executive VP & CFO	N/D	N/D	N/D
Ms. Patricia Carr	Senior VP & Chief Accounting Officer	N/D	N/D	1972
Ms. Andrea N. Flynn Ph.D.	VP & Head of Investor Relations	N/D	N/D	N/D
Ms. Neena M. Patil J.D.	Executive VP & Chief Legal Officer	331,61k	N/D	1976
Ms. Heidi Manna	Executive VP & Chief People Officer	N/D	N/D	1972
Dr. Jed Black M.D.	Senior Vice President of Sleep & CNS Medicine	N/D	N/D	N/D
Ms. Samantha Pearce	Senior Vice President of Europe & International	N/D	N/D	1966

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Jazz Pharmaceuticals plc al 1 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.